Durvalumab Plus Tremelimumab in Solid Tumors: A Systematic Review
Sign Up to like & getrecommendations! Published in 2021 at "Advances in Therapy"
DOI: 10.1007/s12325-021-01796-6
Abstract: Cancer immunotherapy represents one of the most important innovations in modern medicine. Durvalumab is an anti-programmed cell death ligand 1 (PDL-1) agent which is currently under investigation in several studies in combination with the anti-cytotoxic… read more here.
Keywords: tremelimumab; solid tumors; durvalumab; plus tremelimumab ... See more keywords
Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN.
Sign Up to like & getrecommendations! Published in 2022 at "ESMO open"
DOI: 10.1016/j.esmoop.2022.100408
Abstract: BACKGROUND In the phase III CASPIAN study, first-line durvalumab in combination with etoposide plus either cisplatin or carboplatin (EP) significantly improved overall survival (OS) versus EP alone in extensive-stage small-cell lung cancer (ES-SCLC). Durvalumab plus… read more here.
Keywords: durvalumab; durvalumab plus; tremelimumab plus; plus tremelimumab ... See more keywords
Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study.
Sign Up to like & getrecommendations! Published in 2020 at "Lung cancer"
DOI: 10.1016/j.lungcan.2020.09.003
Abstract: OBJECTIVES In the phase III CASPIAN study, first-line durvalumab plus etoposide in combination with either cisplatin or carboplatin (EP) significantly improved overall survival (primary endpoint) versus EP alone in patients with extensive-stage small-cell lung cancer… read more here.
Keywords: cancer; durvalumab plus; platinum etoposide; lung cancer ... See more keywords
Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU)
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.22.00205
Abstract: PURPOSE Homologous recombination repair gene mutations (HRRm) are common in urothelial carcinoma (UC), rendering tumor cells sensitive to poly (ADP-ribose) polymerase (PARP) inhibition. We assessed efficacy and safety of durvalumab (anti–programmed cell death ligand-1) plus… read more here.
Keywords: durvalumab; phase trial; plus olaparib; urothelial carcinoma ... See more keywords
First-Line Durvalumab Plus Platinum-Etoposide Versus Platinum-Etoposide for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis
Sign Up to like & getrecommendations! Published in 2020 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2020.602185
Abstract: Background The aim of the present study was to evaluate the cost-effectiveness of durvalumab plus platinum–etoposide versus platinum–etoposide as first-line treatments for small-cell lung cancer from the perspective of the US payer. Methods This study… read more here.
Keywords: plus platinum; cost; durvalumab plus; platinum etoposide ... See more keywords
Cost-effectiveness analysis of durvalumab plus chemotherapy as first-line treatment for biliary tract cancer
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Public Health"
DOI: 10.3389/fpubh.2023.1046424
Abstract: Objective The TOPAZ-1 trial reported a significant survival benefit of durvalumab in combination with chemotherapy for the first-line treatment of biliary tract cancer (BTC). However, no studies have evaluated the economics of this treatment option.… read more here.
Keywords: plus chemotherapy; cost; treatment; durvalumab plus ... See more keywords